fleroxacin has been researched along with Cystic Fibrosis of Pancreas in 5 studies
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.
fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen patients with cystic fibrosis and 12 healthy control volunteers received a single oral 800 mg dose of fleroxacin and 800 mg every day for 5 days." | 7.68 | Altered disposition of fleroxacin in patients with cystic fibrosis. ( LeBel, M; Mimeault, J; Ruel, M; Seelmann, R; Sörgel, F; Vallée, F, 1990) |
| "We evaluated fleroxacin, a newer fluoroquinolone, against isolates from sputum from patients with cystic fibrosis." | 7.68 | Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis. ( Akaniro, JC; Marks, MI; Stutman, HR; Vidaurre, CE, 1990) |
| "Thirteen patients with cystic fibrosis and 12 healthy control volunteers received a single oral 800 mg dose of fleroxacin and 800 mg every day for 5 days." | 3.68 | Altered disposition of fleroxacin in patients with cystic fibrosis. ( LeBel, M; Mimeault, J; Ruel, M; Seelmann, R; Sörgel, F; Vallée, F, 1990) |
| "We evaluated fleroxacin, a newer fluoroquinolone, against isolates from sputum from patients with cystic fibrosis." | 3.68 | Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis. ( Akaniro, JC; Marks, MI; Stutman, HR; Vidaurre, CE, 1990) |
| " Although, in patients with CF, the extent of drug absorption varies widely and the rate of absorption is slower, bioavailability is not altered." | 2.40 | Drug disposition in cystic fibrosis. ( Pons, G; Rey, E; Tréluyer, JM, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiao, Y | 1 |
| Kim, TH | 1 |
| Tao, X | 1 |
| Kinzig, M | 1 |
| Landersdorfer, CB | 1 |
| Drescher, SK | 1 |
| Sutaria, DS | 1 |
| Moya, B | 1 |
| Holzgrabe, U | 1 |
| Sörgel, F | 2 |
| Bulitta, JB | 1 |
| Kearns, GL | 1 |
| Rey, E | 1 |
| Tréluyer, JM | 1 |
| Pons, G | 1 |
| Mimeault, J | 1 |
| Vallée, F | 1 |
| Seelmann, R | 1 |
| Ruel, M | 1 |
| LeBel, M | 1 |
| Akaniro, JC | 1 |
| Vidaurre, CE | 1 |
| Stutman, HR | 1 |
| Marks, MI | 1 |
2 reviews available for fleroxacin and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
Topics: Bile; Biotransformation; Child; Child, Preschool; Cystic Fibrosis; Fleroxacin; Humans; Liver; Liver | 1993 |
Drug disposition in cystic fibrosis.
Topics: Absorption; Anti-Infective Agents; Ciprofloxacin; Cloxacillin; Cyclosporine; Cystic Fibrosis; Flerox | 1998 |
3 other studies available for fleroxacin and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Biotransformation; Body Composition; | 2018 |
Altered disposition of fleroxacin in patients with cystic fibrosis.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug | 1990 |
Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ciprofloxacin; Cystic Fibrosis; Fleroxacin; | 1990 |